Azepines and piperidines with dual norepinephrine dopamine uptake inhibition and antidepressant activity

ACS Medicinal Chemistry Letters

Volumn 4, Issue 1, 2013, Pages 46-51

  Brown, Dean G ^a   Bernstein, Peter R ^a   Wu, Ye ^a   Urbanek, Rebecca A ^a   Becker, Christopher W ^a   Throner, Scott R ^a   Dembofsky, Bruce T ^a   Steelman, Gary B ^a   Lazor, Lois A ^a   Scott, Clay W ^a   Wood, Michael W ^a   Wesolowski, Steven S ^a   Nugiel, David A ^c   Koch, Stephanie ^a   Yu, Jian ^a   Pivonka, Donald E ^a   Li, Shuang ^a   Thompson, Carol ^a   Zacco, Anna ^a   Elmore, Charles S ^a   Schroeder, Patricia ^a   Liu, Jianwei ^a   Hurley, Christopher A ^b   Ward, Stuart ^b   Hunt, Hazel J ^b   Williams, Karen ^b   McLaughlin, Joseph ^a   Hoesch, Valerie ^a   Sydserff, Simon ^a   Maier, Donna ^a   Aharony, David ^a   more..

^a ASTRAZENECA   (United Kingdom)

^b Argenta Discovery Ltd   (United Kingdom)

^c AstraZeneca Pharmaceuticals ^*

Author keywords

antidepressant; dopamine; norepinephrine; uptake inhibitors

Indexed keywords

AZEPINE DERIVATIVE; DOPAMINE TRANSPORTER; NOMIFENSINE; NORADRENALIN TRANSPORTER; PIPERIDINE DERIVATIVE; SEROTONIN TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; FORCED SWIMMING TEST; IC 50; LOCOMOTION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY;

RATTUS; RODENTIA;

EID: 84872319629     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml300262e     Document Type: Article

References (26)

1. Nemeroff, C. B. Prevalence and Management of Treatment-Resistant Depression J. Clin. Psychiatry 2007, 68 (Suppl. 8) 17-25
2. Papakostas, G. Limitations of Contemporary Antidepressants: Tolerability J. Clin. Psychiatry 2007, 68, 11-17
3. Liu, S.; Molino, B. F. Recent Developments in Monoamine Reuptake Inhibitors Annu. Rep. Med. Chem. 2007, 42, 13-26
4. Wong, D. T.; Perry, K. W.; Bymaster, F. P. The Discovery of Fluoxetine Hydrochloride (Prozac) Nat. Rev. Drug Discovery 2005, 4 (9) 764-774
5. Schatzberg, A. F. Efficacy and Tolerability of Duloxetine, a Novel Dual Uptake Inhibitor, in the Treatment of Major Depressive Disorder J. Clin. Psychiatry 2003, 64 (Suppl. 13) 30-37
6. Tran, P.; Skolnick, P.; Czobor, P.; Huang, N. Y.; Bradshaw, M.; McKinney, A.; Fava, M. Efficacy and Tolerability of the Novel Triple Uptake Inhibitor Amitifadine in the Treatment of Patients with Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial J. Psychiatric Res. 2012, 46, 692-693
7. Hunt, P.; Kannengiesser, M.-H.; Raynaud, J.-P. Nomifensine: A New Potent Inhibitor of Dopamine Uptake into Synaptosomes from Rat Brain Corpus Striatum J. Pharm. Pharmacol. 1974, 26 (5) 370-371
8. Tuomisto, J. Nomifensine and its Derivatives as Possible Tools for Studying Amine Uptake Eur. J. Pharmacol. 1977, 42 (2) 101-106
9. Nielson, J. L.; Lund, N. O. Drug Fever due to Nomifensine Treatment in Patients with Endogenous Depression Int. Pharmacopsychiatry 1981, 16, 66-68
10. Salama, A.; Mueller-Eckhardt, C. Two Types of Nomifensine-Induced Immune Haemolytic Anaemias: Drug-Dependant Densitizatioin and/or Autoimmunization Br. J. Hamaetol. 1986, 64, 613-620
11. List of Drug Products That Have Been Removed From the Market for Reasons of Safety or Effectiveness. Fed. Regist. 1998, 63 (195), 54082-54089.
12. Obach, S. R.; Dalvie, D. K. Metabolism of Nomifensine to a Dihydroisoquinolinium Ion Metabolite by Human Myleoperoxidase, Hemoglobin, Monoamine Oxidase A, and Cythochrome P450 Enzymes Drug Metab. Dispos. 2006, 34 (8) 1310-1316
13. Liu, S.; Pechulis, A. D.; Beck, J. P.; Yang, Z.; Vellekoop, A. S.; Sweet, M. P.; Harms, A. E.; Wolf, M. A.; Hassler, C.; Klos, A. M.; Opalks, C. J.; Crocker, P. J.; Khmelnitsky, Y.; Smith, M. A.; Molino, B. F. Heterocycle-Fused 4-Phenyl Tetrahydroisoquinolines as Dual NET/DAT Inhibitors, Presented at 243rd ACS National Meeting & Exposition, San Diego, CA, United States, March 25-March 29, 2012; MEDI-372.
14. Tuthill, P. A.; Seida, P. R.; Barker, W.; Cassel, J. A.; Belanger, S.; DeHaven, R. N.; Koblish, M.; Gottshall, S. L.; Little, P. J.; Dehaven-Hudkins, D. L.; Dolle, R. E. Azepinone as a Conformational Constraint in the Design of κ-Opiod Receptor Agonists Bioorg. Med. Chem. Lett. 2004, 14, 5693-5697
15. 2R=CHR Olefin Metathesis Catalysts: An Organometallic Success Story Acc. Chem. Res. 2001, 34, 18-29
16. Sudhakar, A. R.; Tang, S. Optically Active Intermediates for the Preparation of Optically Active Substituted Oximes, Hydrazones and Olefins Useful as Neurokinin Antagonists, U.S. Patent 6,265,614, B1 July 24, 2001.
17. Nafie, L. A.; Dukor, R. K. In Applications of Vibrational Optical Activity in the Pharmaceutical Industry; Pivonka, D. E.; Chalmers, J. M.; Griffitsh, P. R., Eds.; John Wiley and Sons: Chichester, West Sussex, England; pp 129-154 (2-7).
18. Crawford, T. D. Ab initio calculation of molecular chirooptical properties Theor. Chem. Acc. 2006, 115, 227-245
19. Emonds-Alt, X.; Gueule, P.; Proietto, V.; Van Broeck, D. 1-Azoniabicyclo [2.2.1.]heptanes, Method of Preparing Them and Pharmaceutical Compositions in Which they are Present. U.S. Patent 5,679,693, October 21, 1997.
20. Chan, J. H. T.; Elix, J. A.; Ferguson, B. A. Anelated Furans. XVII. The Wittig Reaction of Benzofuranones Aust. J. Chem. 1975, 28, 1097-1111
21. Kunstmann, R.; Gerhards, H.; Kruse, H.; Leven, M.; Paulus, E. F.; Schacht, U.; Schmitt, K.; Witte, P. U. Resolution, Absolute Stereochemistry, and Enantioselective Activity of Nomifensine and Hexahydro-1H-indeno[1,2-b] pyridines J. Med. Chem. 1987, 30, 798-804
22. Pogun, S.; Scheffel, U.; Kuhar, M. J. Cocaine Displaces [3H]WIN 35,428 binding to Dopamine Uptake Sites in Vivo More Rapidly than Mazindol or GBR 12909 Eur. J. Pharmacol. 1991, 198, 203-205
23. 3H]MeNR: Ghose, S.; Fujita, M.; Morrison, P.; Uhl, G.; Murphy, D. L.; Mozley, P. D.; Schou, M.; Halldin, C.; Innis, R. Synapse 2005, 56, 100-104
24. 3H]PE2I: A Radiopharmaceutical for in vivo Exploration of the Dopamine Transporter CNS Neurosci. Ther. 2008, 14, 47-64
25. Haunso, A.; Buchanan, D. J. Pharmacological Characterization of a Fluorescent Uptake Assay for the Noradrenaline Transporter J. Biomol. Screening 2007, 12, 378-384
26. Mitchell, H. A.; Ahem, T. H.; Liles, C.; Javors, M. A.; Weinshenker, D. The Effects of Norepinephrine Transporter Inactivation on Locomotor Activity in Mice Biol. Psychiatry 2006, 60, 1046-1052